Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia
- 30 April 2006
- journal article
- research article
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 43 (4) , 752-759
- https://doi.org/10.1016/j.jvs.2005.11.041
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Increase in Peripheral Blood Flow by Intravenous Administration of Prostaglandin E1 in Patients with Peripheral Arterial Disease, Accompanied by Up-Regulation of Hepatocyte Growth FactorHypertension Research, 2004
- Angiogenic effects of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cellsBlood, 2003
- Clinical benefit of Prostaglandin E1-treatment of patients with ischemic heart disease: stimulation of therapeutic angiogenesis in vital and infarcted myocardiumBiomedicine & Pharmacotherapy, 2003
- Prostaglandin E1 Improves Endothelial Function in Critical Limb IschemiaJournal of Cardiovascular Pharmacology, 2003
- Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1Prostaglandins, Leukotrienes & Essential Fatty Acids, 2002
- Vascular adhesion molecule-1 and markers of platelet function before and after a treatment with iloprost or a supervised physical exercise program in patients with peripheral arterial disease.Life Sciences, 2001
- Medical Treatment of Peripheral Arterial Disease and ClaudicationNew England Journal of Medicine, 2001
- Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow.Scandinavian Journal of Clinical and Laboratory Investigation, 1998
- Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion.British Journal of Clinical Pharmacology, 1995
- IloprostDrugs, 1992